ClinicalTrials.gg
Enrolling by invitationNCT07567716Updated May 5, 2026

Infiltration Pattern of Locally Advanced ESCC

An observational study in Esophageal Squamous Cell Carcinoma (ESCC), Infiltration and Tumour, sponsored by Shanghai Chest Hospital. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Chest Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital — 7 open to participants now, 7 under way, none of them phase 3. Esophageal Squamous Cell Carcinoma · Shanghai Chest Hospital.

Started
2025
the only one that year
Observational
2 of 12
1 open now
Registered
10th of 12
by date

Among the 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

7 of the 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Esophageal Squamous Cell Carcinoma by Shanghai Chest Hospital, or all of them as a file.
02

Study summary

Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Infiltration
  • Tumour

Keywords

  • esophageal squamous cell carcinoma
  • infiltration pattern
  • prognosis
  • resection margin
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with c/ycT2-3 esophageal squamous cell carcinoma (ESCC) who underwent McKeown esophagectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cervical or thoracic ESCC
  • received esophagectomy
  • preoperative stage T2-3
  • no viable multiple lesions
  • received McKeown esophagectomy

Exclusion criteria

Exclusion Criteria:

  • Incomplete clinical materials
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • esophagectomy group

    Receive esophagectomy for treatment

    Other: Esophagectomy · Procedure: Esophagectomy

Interventions

  • OtherEsophagectomy

    Esophagectomy by McKeown method

  • ProcedureEsophagectomy

    Esophagectomy for ESCC

06

What researchers measure

Primary outcomes

  1. Infiltration pattern

    Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.

    Time frame: Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.

07

Study locations

1 site
08

References and documents

Publications

  • Ma GW, Rong TH, Wu QL, Long H, Fu JH, Lin P, Huang ZF, Zeng CG, Li XD, Zhang X, Zhang LJ, Wang JY, Hu Y, Deng BF. [Giant pathologic section in the study of optimal length of surgical resection for esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):472-4. Chinese. PubMed 14575573 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Apr 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 5, 2026
StartActual
Oct 1, 2025
Primary completionActual
Apr 1, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567716
Responsible party
Zhigang Li (Prof., Shanghai Chest Hospital) — Principal investigator
First posted
May 5, 2026
Start date
Oct 1, 2025
Primary completion
Apr 1, 2026
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion